Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Oragenics, Inc. (OGEN : AMEX)

• Company Description    Oragenics Inc is a biotechnology company focused on the development and licensure of innovative products and technologies for improving human health. Number of Employees: 5

• Price / Volume Information    Yesterday's Closing Price: $1.32 Daily Weekly Monthly 20 Day Moving Average: 218,859 shares Shares Outstanding: 4.13 (millions) Market Capitalization: $5.45 (millions) Beta: 0.83 52 Week High: $14.10 52 Week Low: $1.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.94% 1.67% 12 Week 5.60% -3.01% Year To Date -88.10% -89.69%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1990 MAIN STREET SUITE 750 - SARASOTA,FL 34236 USA ph: 813-286-7900 fax: 813-286-7904 None http://www.oragenics.com

• General Corporate Information    Officers Kimberly M. Murphy - Chief Executive Officer; Chief Financial Officer; Charles L. Pope - Executive Chairman and Director Joseph Michael Redmond - Interim Principal Executive Officer; President Robert C. Koski - Director Frederick W. Telling - Director Peer Information Oragenics, Inc. (CORR.) Oragenics, Inc. (RSPI) Oragenics, Inc. (CGXP) Oragenics, Inc. (BGEN) Oragenics, Inc. (GTBP) Oragenics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 684023609 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 4.13 Most Recent Split Date: 6.00 (0.03:1) Beta: 0.83 Market Capitalization: $5.45 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 79.76% vs. Previous Quarter: 13.97% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - -3,614.27 ROA 09/30/25 - - 06/30/25 - -324.80 03/31/25 - -311.83 Current Ratio 09/30/25 - - 06/30/25 - 0.50 03/31/25 - 1.04 Quick Ratio 09/30/25 - - 06/30/25 - 0.50 03/31/25 - 1.04 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Book Value 09/30/25 - - 06/30/25 - -2.59 03/31/25 - 0.17 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - - 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - - 03/31/25 - 0.00

Powered by Zacks Investment Research ©